![Philippe Remes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Philippe Remes
Plus aucun poste en cours
Profil
Philippe Remes worked as Vice President-Investor Relations at GenOdyssee SA from 2009 to 2011.
Anciens postes connus de Philippe Remes
Sociétés | Poste | Fin |
---|---|---|
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Public Communications Contact | 11/05/2011 |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |